Concise review: Transmissible animal tumors as models of the cancer stem-cell process

Stem Cells

Volumn 29, Issue 12, 2011, Pages 1909-1914

  O'Neill, Iain D ^a  

^a Centre d'Affaires Poincare   (France)

Author keywords

Cancer stem cell; Canine transmissible venereal tumor; Experimental models; Tasmanian devil facial tumor disease

Indexed keywords

ALLOGRAFT; ANIMAL DISEASE; ANTIGEN EXPRESSION; CANCER STEM CELL; CELL HETEROGENEITY; CELL POPULATION; CELL RENEWAL; CLONAL VARIATION; DEVIL FACIAL TUMOR DISEASE; DISEASE TRANSMISSION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; TRANSMISSIBLE VENEREAL TUMOR; TUMOR GENE; TUMOR MODEL;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CLONE CELLS; DISEASE TRANSMISSION, INFECTIOUS; FACIAL NEOPLASMS; GENETIC HETEROGENEITY; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PHENOTYPE; VENEREAL TUMORS, VETERINARY;

ANIMALIA; SARCOPHILUS HARRISII;

EID: 81855211049     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.751     Document Type: Review

References (55)

1. Murchison EP. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene 2009;27:S19-S30.
2. Murchison EP, Tovar C, Hsu A et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010;327:84-87.
3. Murgia C, Pritchard JK, Kim SY et al. Clonal origin and evolution of a transmissible cancer. Cell 2006;126:477-487. (Pubitemid 44163607)
4. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
5. Jordan CT. Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 2009;4:203-205.
6. Siddle HV, Kreiss A, Eldridge MD et al. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 2007;104:16221-16226. (Pubitemid 350099388)
7. Rebbeck CA, Thomas R, Breen M et al. Origins and evolution of a transmissible cancer. Evolution 2009;63:2340-2349.
8. Loh R, Hayes D, Mahjoor A et al. The immunohistochemical characterisation of devil facial tumour disease (DFTD) in Tasmanian devils (Sarcophilus harrissii). Vet Pathol 2006;43:896-903. (Pubitemid 44801381)
9. Tovar C, Obendorf D, Murchison EP et al. Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: Immunohistochemistry studies. Vet Pathol doi: 10.1177/0300985811400447.
10. Harmelin A, Pinthus JH, Katzir N et al. Use of a murine xenograft model for canine transmissible venereal tumor. Am J Vet Res 2001;62:907-911. (Pubitemid 33662355)
11. Stettner N, Brenner O, Eilam R et al. Pegylated liposomal doxorubicin as a chemotherapeutic agent for treatment of canine transmissible venereal tumor in murine models. J Vet Med Sci 2005;67:1133-1139. (Pubitemid 41758223)
12. Kreiss A, Tovar C, Obendorf DL et al. A murine xenograft model for a transmissible cancer in Tasmanian devils. Vet Pathol 2010;48:475-481.
13. Nowinsky M. Zur Frage ueber die Impfung der krebsigen Geschwuelste. Zentralbl Med Wissensch 1876;14:790-791.
14. Sticker A. Transplantables Rundzellensarkom des Hundes. Z Krebsforsch 1906;4:227-314.
15. Mozos E, Mendez A, Gomez-Villamandos JC et al. Immunohistochemical characterization of canine transmissible venereal tumor. Vet Pathol 1996;33:257-263. (Pubitemid 126481503)
16. Marchal T, Chabanne L, Kaplanski C et al. Immunophenotype of the canine transmissible venereal tumour. Vet Immunol Immunopathol 1997;57:1-11. (Pubitemid 27296974)
17. Cohen D. The canine transmissible venereal tumor: A unique result of tumor progression. Adv Cancer Res 1985;43:75-112.
18. Das U, Das AK. Review of canine transmissible venereal sarcoma. Vet Res Commun 2000;24:545-556.
19. Welsh JS. Contagious cancer. Oncologist 2011;16:1-4.
20. O'Neill ID. Tasmanian devil facial tumor disease: Insights into reduced tumor surveillance from an unusual malignancy. Int J Cancer 2010;127:1637-1642.
21. McCallum H. Tasmanian devil facial tumour disease: Lessons for conservation biology. Trends Ecol Evol 2008;23:631-637.
22. Jones ME, Cockburn A, Hamede R et al. Life-history change in disease-ravaged Tasmanian devil populations. Proc Natl Acad Sci USA 2008;105:10023-10027.
23. Hamede R, McCallum HI, Jones ME. Seasonal, demographic and density-related patterns of contact between Tasmanian devils: Implications for transmission of devil facial tumour disease. Aust Ecol 2008;33:614-622.
24. Obendorf DL, McGlashan ND. Research priorities in the Tasmanian devil facial tumour debate. Eur J Oncol 2008;13:229-238.
25. Loh R, Bergfeld J, Hayes D et al. The pathology of devil facial tumour disease (DFTD) in Tasmanian devils (Sarcophilus harrissii). Vet Pathol 2006;43:890-895. (Pubitemid 44785962)
26. Kreiss A, Cheng Y, Kimble et al. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS ONE 2011;6:e22402.
27. Liao KW, Lin ZY, Pao HN et al. Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. J Vet Diagn Invest 2003;15:399-406.
28. Thomas R, Rebbeck C, Leroi AM et al. Extensive conservation of genomic imbalances in canine transmissible venereal tumors (CTVT) detected by microarray-based CGH analysis. Chromosome Res 2009;17:927-934.
29. Rebbeck CA, Leroi AM, Burt A. Mitochondrial capture by a transmissible cancer. Science 2011;331:303.
30. Pearse A-M, Swift K. Transmission of devil facial-tumour disease. Nature 2006;439:549.
31. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
32. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009;324:1670-1673.
33. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009;138:822-829.
34. Cockrill JM, Beasley JN. Transmission of transmissible venereal tumor of the dog to the coyote. Am J Vet Res 1979;40:409-410.
35. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006;19:659-668.
36. Fargeas CA, Florek M, Huttner WB et al. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J Biol Chem 2003;278:8586-8596. (Pubitemid 36800613)
37. Rinkevich B. Stem cells: Autonomy interactors that emerge as causal agents and legitimate units of selection. In: Rinkevich B, Matranga V et al., eds. Stem Cells in Marine Organisms. Dordrecht, Heidelberg: Springer, 2009:1-20.
38. Tu SM. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. Cancer Treat Res 2010;154:v-239.
39. Huang L, Espinoza C, Welsh R. Malignant peripheral nerve sheath tumor with divergent differentiation. Arch Pathol Lab Med 2003;127:e147-e150.
40. Gershon TR, Oppenheimer O, Chin SS et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia 2005;7:575-584. (Pubitemid 40967758)
41. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci USA 2006;103:3752-3757. (Pubitemid 43376627)
42. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23:746-759.
43. Ramgolam K, Lauriol J, Lalou C et al. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS ONE 2011;6:e18784.
44. Miller W, Hayes VM, Ratan A et al. From the cover: Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci USA 2011;108:12348-12353.
45. Pai CC, Kuo TF, Mao SJ et al. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Vet Immunol Immunopathol 2011;139:187-199.
46. Dhodapkar MV. Immunity to stemness genes in human cancer. Curr Opin Immunol 2010;22:245-250.
47. Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009;27:1734-1740.
48. Pellegatta S, Poliani PL, Corno D et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006;66:10247-10252. (Pubitemid 44799739)
49. Belov K. The role of the major histocompatibility complex in the spread of contagious cancers. Mamm Genome 2011;22:83-90.
50. Croker AK, Allan AL. Cancer stem cells: Implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008;12:374-390. (Pubitemid 351555122)
51. Mimeault M, Batra SK. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol 2010;25:1057-1073.
52. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
53. Boiko AD, Razorenova OV, van de Rijn M et al. Human melano-mainitiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-137.
54. Ross RA, Spengler BA. Human neuroblastoma stem cells. Semin Cancer Biol 2007;17:241-247. (Pubitemid 46413078)
55. Spyra M, Kluwe L, Hagel C et al. Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS ONE 2011;6:e21099.